Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

China flag China · Delayed Price · Currency is CNY
80.01
-2.14 (-2.60%)
Mar 9, 2026, 3:00 PM CST
-6.97%
Market Cap 21.18B
Revenue (ttm) 812.73M
Net Income (ttm) -160.70M
Shares Out 264.71M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE 90.75
Dividend n/a
Ex-Dividend Date n/a
Volume 3,025,804
Average Volume 3,133,992
Open 80.92
Previous Close 82.15
Day's Range 78.51 - 81.92
52-Week Range 75.10 - 134.17
Beta 0.20
RSI 41.78
Earnings Date Mar 28, 2026

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydroch... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 910
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688266
Full Company Profile

Financial Performance

In 2025, SHA:688266's revenue was 812.73 million, an increase of 52.50% compared to the previous year's 532.95 million. Losses were -160.70 million, 16.6% more than in 2024.

Financial Statements

News

There is no news available yet.